Under the Paperwork
Substitute for form 1449A/PTO

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
to a collection of information unless it disables a unit of the commence of the collection of information unless it disables a unit of the colle

Under the Paperwork Reduction Act of 1995, no persons are required to respond to

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 1 of 2

a collection of information unless it displays a	Valid OMB control number.
Application Number	10/656,059
Filing Date	September 5, 2003
First Named Inventor	Hul Cai
Group Art Unit .	
Examiner Name	
Attorney Docket Number	PRD0036NP

	Г	U.S. Patent Do	cument	U.S. PATENT DOCUMENTS	1	
				Name of Patentee or Applicant	Date of Publication	Pages, Columns, Lines,
Examiner	Cite		Kind Code ²	of Cited Document	of Cited Document	where relevant passages or relevant figures appear
Initials	No.1	Number	(if known)		mm-dd-yyyy	or relevant rigures appear
	-					
						*
		1				
	-					
	-					
			1			
	1					
	 	 				
					 	
						//PI
				CN PATENT DOCUMENTS		

			FORI	EIGN PATENT DOCUMENTS			
	Foreign Patent Document			Name of Patentee or	Date of Publication of Cited Document	where relevant	
Examiner Cite Initials No.1	Office ³	Number ⁴ I	KindCode ⁵	Applicant of Cited Document	mm-dd-yyyy	passages or relevant figures appear	Τ°
	wo	9940914		Zeneca Limited	08-19-1999		
	EP	1088824	А3	Pfizer Products Inc.	06-27-2001		
	EP	1136071	A2	Pfizer Products Inc.	09-26-2001		<u> </u>
							ļ
				•			<u> </u>
	-						
		Cite No.1 Office³	Cite No.1 Office Number Number No.1 WO 9940914 EP 1088824	Foreign Patent Document	Name of Patentee or Applicant of Cited Document WO 9940914 Zeneca Limited EP 1088824 A3 Pfizer Products Inc.	Foreign Patent Document Name of Patentee or Applicant of Cited Document No.¹ Office³ Number⁴ KindCode⁵ Applicant of Cited Document WO 9940914 Zeneca Limited 08-19-1999 EP 1088824 A3 Pfizer Products Inc. 06-27-2001	Foreign Patent Document Name of Patentee or Applicant of Cited Document WO 9940914 EP 1088824 A3 Pfizer Products Inc. Date of Publication of Cited Document mm-dd-yyyy Pages, Columns, Lines, where relevant passages or relevant figures appear Name of Patentee or Applicant of Cited Document Name of Patentee or Of Cited Document N

Considered Signature *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document, 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Examiner Signature

PTC/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE tk Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1448

ORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 2 of 2

a conception or attorniation anicos it displays	3 TONG CHICAGO CONTOURS CONTOU
Application Number	10/656,059
Filing Date	September 5, 2003
First Named Inventor	Hui Cai
Group Art Unit	
Examiner Name	
Attomey Docket Number	PRD0036NP

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item	
Examiner's	Cite	(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s),	T ²
Initials*	No.1	publisher, city and/or country where published	
muais	140.	DETTY, M.R. et al. Studies Toward Alkythiophene-2-Carboxaldehydes. Reduction of 3-Alkenylthiophenes with	
Λ)	Triethylsilane/Trifluoroacetic Acid. Regioselectivity in Formylation Reactions of 3-Alkylthiophenes. Heterocycles (1995)	
11/1/	/	40(2):925-937	
	/	KONDO, K. et al. Synthetic Utility of tert-Butyl Azidoacetate on the Hemetsberger-Knittel Reaction (Synthetic Studies of	
7		Indoles and Related Compounds Part 47), Chem. Pharm. Bull. (1999) 47(9):1227-1231	
70		IRIARTE, J. et al. The Chlorination of Thiophene-2-aldehyde and Ethyl Thiophene-2-carboxylate in the Presence of Excess	
		Aluminum Chlonde, J. Het. Chem. (1976) 13:393-394.	
		ARRANG, JM. et al. Auto-Inhibition of Brain Histamine Release Mediated by a Novel Class (H3) of Histamine Receptor.	
		Nature (1983) 302:832-837 ASH, A.S.F.; SCHILD, H.O. Receptors Mediating Some Actions of Histamine. Br. J. Pharmac. Chemother. (1966)	
1 1		ASH, A.S.F.; SCHILD, H.O. Receptors Mediating Some Actions of Histamine. Br. J. Pharmac. Chemother. (1966) 27:427-439	
		BARGER, G.; DALE, H.H. Chemical Structure and Sympathomimetic Action of Amines. J. Physiol. (1910) 41:19-59	
1 1		Reprinted in Adventures in Physiology, Sir Henry H. Dale, Ed.; The Wellcome Trust: London, 1965; pp 67-98.	
		BLACK, J.W. et al. Definition and Antagonism of Histamine H2-Receptors. Nature (1972) 236:385-390	
		GANTZ, I. et al. Molecular Cloning of a Gene Encoding the Histamine H2 Receptor. Proc. Natl. Acad. Sci. USA (1991)	
1	\	88:429-433	
1		HILL, S.J. et al. International Union of Pharmacology, XIII. Classification of Histamine Receptors. Pharmacol. Rev. (1997)	
1		49(3):253-278	
		LIU, C. et al. Cloning and Pharmacological Characterization of a Fourth Histamine Receptor (H4) Expressed in Bone	
		Marrow. Mol. Pharmacol. (2001) 59(3):420-426	
		LOVENBERG, T.W. et al. Cloning and Functional Expression of the Human Histamine H3 Receptor. Mol. Pharmacol. (1999) 55(6):1101-1107	
		MORSE, K.L. et al. Cloning and Characterization of a Novel Human Histamine Receptor. J. Pharmacol. Exp. Ther.	
1 1		(2001) 296(3):1058-1066	
		NGUYEN, T. et al. Discovery of a Novel Member of the Histamine Receptor Family. Mol. Pharmacol. (2001) 59(3):427-	
i		433	
		ODA, T. et al. Molecular Cloning and Characterization of a Novel Type of Histamine Receptor Preferentially Expressed in Leukocytes. J. Biol. Chem. (2000) 275(47):36781-36786	
7		RAIBLE, D.G. et al. Pharmacologic Characterization of a Novel Histamine Receptor on Human Eosinophils. Am. J. Respir, Crit. Care Med. (1994) 149:1508-1511	
1/		YAMASHITA, M. et al. Expression Cloning of a cDNA Encoding the Bovine Histamine H1 Receptor. Proc. Natl. Acad. Sci. USA (1991) 88:11515-11519	
- 11/		ZHU, Y. et al. Cloning, Expression, and Pharmacological Characterization of a Novel Human Histamine Receptor. Mol.	
Y 1		Pharmacol. (2001) 59(3):434-441	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA

22313-1450.

Date Considered



SUBMISSION UNDER MPEP 609 D

Application Number	10/656,059
Filing Date	September 5, 2003
First Named Inventor	Hui Cai et al.
Group Art Unit	1614
Examiner Name	
Attorney Docket Number	PRD-36

		Page 1 of 1	_	Attomey D	ocket Nun	nber	PRD-36		
		U.S. P.		OCUMENTS					
Examiner Initials	Cite	Name of Patentee or Applicant of Cited Document	-			d Code ²	Pages, Columa where relevant p relevant figure	t passages o	
	NO.				-				
	1								
							:		
	<u></u> i	FOREIGN	I PATEN	T DOCUMEN	TS				
Examiner Initials	Name of Patentee or		100000000000000000000000000000000000000	wh		where re	Pages, Columns, Lines, where relevant passages or relevant figures appear		
							•		
		OTHER PRIOR ART - NO	ON PATE	NT LITERATUR	RE DOCUMEN	rrs			
Examiner 's Initials*	Cite No.¹	Include-name of the author (in Control of the item (book, magazine volume-issue number(s	APITOL I , journal,), publish	LETTERS), titi serial, sympo ner, city and/or	le of the articsium, catalor r country wh	cle (when g, etc.), d ere publis	ate, page(s), shed	T²	
		PCT International Search Report, dated	March 2,	2004, for PCT A	Appin. No. PC	T/US03/28	017		
				Date			, ,		

PTC/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to

	1449A/PTO

Examiner

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 1 of 1

a collection of information unless it displays	a valid OMB control number.
Application Number	10/656,059
Filing Date	September 5, 2003
First Named Inventor	Hui Cai et al.
Group Art Unit	1614
Examiner Name	
Attorney Docket Number	PRD-36

	U.S. Patent Do	cument			
Cite No.	Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear
			· · · · · · · · · · · · · · · · · · ·		
		Cite	Cite Kind Code ²	Cite No.¹ Number (if known) Name of Patentae or Applicant of Cited Document	Cite No.¹ Number (if known) of Cited Document of Cited Document mm-dd-yyyy

			FC	DREIGN PATENT DOCUMENTS			
Examiner Initials	Cite	Foreign Office ³	Patent Document Number ⁴ KindCode	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Cotumns, Lines, where relevant passages or relevant figures appear	™
		ΕP	0 282 133	Janssen Pharmaceutica N.V.	09-14-1988		
		EP	0 180 500	Lipha	05-07-1986		L.,
17		WO.	02/072548	Ortho-McNeil Pharmaceutical, Inc.	09-19-2002		
V							
				·			
							<u> </u>
		1		•			
		-//	-			/ /	

Date Considered *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 See attached Kinds of U.S. Patent Occuments. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450